• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    PW Medtech Group (SEHK:1358) Stock Faces Margin Crunch Despite Rich P E

    Simply Wall St·09/23/2026 11:28:40
    Listen to the news

    PW Medtech Group is priced by the market like a problem stock, with the share price down over the past week and quarter, yet the latest earnings show a more nuanced story. The headline is not revenue in this medical equipment business. The real story is the heavy profit squeeze, with trailing net profit margin at 5.4% compared with 17.3% a year earlier, while the stock still trades on a P/E of 25.3x. That gap between a rich multiple and strained profitability is what investors may want to focus on after this H1 update.

    Concerned that PW Medtech Group carries a 25.3x P/E while net margins are under pressure? Compare it with list of solid balance sheet and fundamentals stocks (198 results).

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs. H1 2025): ¥394.056 million vs. ¥414.373 million (down 4.9%)
    • Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): ¥14.692 million vs. ¥65.999 million (down 77.7%)
    • Basic EPS (H1 2026 vs. H1 2025): ¥0.010068 per share vs. ¥0.044391 per share (down 77.3%)
    • Trailing Twelve Month Net Profit Margin (Latest vs. Prior Year): 5.4% vs. 17.3% (sharp margin compression)

    Prefer clear charts instead of another block of numbers and earnings jargon? See PW Medtech Group’s full financial picture, including how its profitability trends line up with its current valuation, in the interactive company report for PW Medtech Group.

    SEHK:1358 Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026
    SEHK:1358 Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026

    PW Medtech bullish story meets profit reality check

    PW Medtech Group is pitched as a defensive healthcare play, yet the latest figures lean against a strong bullish read. Revenue in H1 2026 dipped slightly, which on its own might be manageable for a consumables heavy business. The sharper issue is earnings power. Core net income and basic EPS fell much faster than sales, so the diversified product set is not currently translating into resilient profitability. That makes the long term healthcare demand story harder to treat as a simple comfort blanket.

    Bearish concerns on margins find clear support

    The cautious narrative around PW Medtech Group finds plenty of backing in these results. Net profit margin on a trailing basis is now 5.4%, down from 17.3% a year earlier, which signals a sizeable squeeze in economic returns. H1 2026 net income and EPS both dropped more than 70% year on year, so pressure is not just a single quarter blip. With the share price also weaker over 3 months, the market reaction lines up with these operational headwinds rather than contradicting them.

    Scan PW Medtech Group’s shrinking 5.4% margin and multi year earnings slide, then review our independent risk analysis for PW Medtech Group which shows 2 important warning signs to see potential hidden structural issues.

    Stay Ahead With Simply Wall St

    PW Medtech Group’s compressed margins and rich P/E make timing and discipline far more important than headlines alone. Register for free with Simply Wall St and add it to your Watchlist so you can track price against fair value and watch how future results affect the risk reward profile. Once you hold the shares, manage the position inside the Portfolio Command Center to cut through market noise and surface only the key events that could change your thesis. Over the long run, you can compare your thinking with other investors through the Community to identify potential catalysts or red flags early and stay a step ahead of the market.

    Seeking Alternatives Beyond PW Medtech?

    The next breakout ideas rarely wait. Momentum shifts, fresh themes start flying and the best setups get caught by early movers while it matters. Scan these under the radar lists and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.